Creating a vaccine to prevent lymphoma in HIV-infected individuals
Official title: Rational Vaccine Design to prevent HIV-Associated Lymphoma
Funded at Fred Hutchinson Cancer Center · NIH-11017842 · Data updated 2026-11-12
This study is working on a new vaccine to help prevent certain types of lymphomas in people with HIV, especially those caused by the Epstein-Barr virus, by boosting the body's ability to fight the virus with special antibodies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $647,437 |
| NIH project number | 5R01CA285227-02 |
| Project ID | NIH-11017842 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are HIV-positive and at increased risk for developing EBV-associated lymphomas.
✕Less likely to help
Patients who are HIV-negative or those who do not have a risk of developing lymphomas may not benefit from this research.
What this research studies
This research focuses on developing a vaccine aimed at preventing lymphomas associated with HIV infection, particularly those driven by the Epstein-Barr virus (EBV). It investigates the role of neutralizing antibodies in providing protection against EBV and aims to elicit high levels of these antibodies through innovative vaccine designs. The approach includes testing various vaccine candidates in animal models to assess their immunogenicity and protective efficacy. If successful, this vaccine could significantly reduce the risk of lymphoma in HIV-infected patients.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly lowers the risk of developing lymphomas in individuals living with HIV.
How similar studies have gone: Previous research has shown promise in using antibody-based approaches for viral infections, indicating potential for success in this novel vaccine strategy.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Mcguire, Andrew — Fred Hutchinson Cancer Center
- Study coordinator: Mcguire, Andrew
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.